Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2305 • ACR Convergence 2025
Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
Alexis Ogdie¹, Ellen Romich², Brian Coburn³, Rebecca Schumacher⁴ and Kaleb Michaud⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²University of Pennsylvania, Media, PA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) are at increased risk for metabolic comorbidities and poorer long-term outcomes compared to the general population. Identifying…
Abstract Number: 1713 • ACR Convergence 2025
Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Abdelhfeez Moshrif⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Al Azhar University, Asyut, Egypt, assyut, Asyut, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Psoriatic arthritis (PsA) remains widely underdiagnosed and misdiagnosed worldwide, leading to delays in appropriate management and increased disease burden. While diagnostic delay has been…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 0578 • ACR Convergence 2025
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Nicole Middaugh⁵, Taylor Blachley⁵, Melissa Eliot⁵ and Alexis Ogdie⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease that can cause substantial impairment in quality of life in affected patients. The Group for Research…
Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Virginia Carrizo Abarza¹, Pankti Mehta², Fadi Kharouf³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…
Abstract Number: 0527 • ACR Convergence 2025
Gaps In Documentation Of Psoriatic Arthritis Domains In General Rheumatologic Practices Compared To Rheumatology-Dermatology Combined Clinics
Alexandra Lauren Rice¹, Sarah Hopkins Gillespie², Nikhil Sai³, Soumya Reddy¹, Joseph Merola⁴, Rebecca Haberman⁵, Alexis Ogdie⁶ and Jose Scher⁷, ¹NYU Grossman School of Medicine, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵NYU Langone Health, New York, NY, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁷New York University School of Medicine, New York, NY
Background/Purpose: To apply current treatment recommendations for psoriatic arthritis (PsA), clinicians must perform a comprehensive assessment of psoriatic disease domains, including a musculoskeletal exam (tender…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: PP07 • ACR Convergence 2025
Beyond the Medication: Creating a Toolbox of Complementary Therapies
Brittany Murray
Background/Purpose: For over 30 years, I have been living with Psoriatic Disease, diagnosed with Psoriasis at 2 years old and Psoriatic Arthritis at 14. My…
Abstract Number: 2369 • ACR Convergence 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease¹, Jessica A. Walsh², Timothy P. Fitzgerald³, Soumya Chakravarty⁴, Elizabeth Adamson⁵, Bruno Emond⁶, Carmine Rossi⁷, Samuel Schwartzbein⁷, Kana Yokoji⁷, Yuxi Wang⁷, Patrick Lefebvre⁷, Dominic Pilon⁷, Shikha Singla⁸ and Joseph F Merola⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³Johnson & Johnson, Horsham, PA, USA, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Analysis Group, Inc., Montreal, QC, Canada, QC, ⁷Analysis Group, Inc., Montreal, QC, Canada, QC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Prior research reported that patients (pts) with psoriatic arthritis (PsA) treated with guselkumab (GUS) were 1.5x more likely to remain persistent with on-label treatment…
Abstract Number: 2340 • ACR Convergence 2025
Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Alexander Garaiman¹, Sophia Massa¹, Elnaz Saeedi², Nicola Gullick³, William Tillett⁴, Raphaël Hurtubise¹, jean-guillaume letarouilly⁵ and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Personalizing care in early psoriatic arthritis (PsA) is challenging. We set out to identify predictors of one-year response on the PASDAS using AI-based methods…
Abstract Number: 2233 • ACR Convergence 2025
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Caleb Marlin¹, Roopa Madhu², Erin Theisen³, Liz Bradshaw⁴, Ce Gao⁵, Thomas Eisenhaure⁶, Nicolas Sugiarto⁷, Accelerating Medicines Partnertship: Autoimmune and Immune Mediated Diseases⁸, Jill Buyon⁹, Michelle Petri¹⁰, Brad Rovin¹¹, Victoria Werth¹², Ellen M. Gravallese¹³, Jennifer Anolik¹⁴, Larry Moreland¹⁵, Laura Donlin¹⁶, Christopher Ritchlin¹⁷, Jose Scher¹⁸, Johann Gudjonsson¹⁹, Wilson Liao²⁰, Alexis Ogdie²¹, Caroline Shiboski²², A. Darise Farris¹, Alan Baer²³, Blake M. Warner²⁴, Jose Clemente²⁵, Adriana Heguy²⁶, Michael Brenner²⁷, Nir Hacohen²⁸, Joel Guthridge¹, Judith James¹, Soumya Raychaudhuri²⁹, Lam Tsoi¹⁹, Xiang Zhou³⁰, Joshua Welch³⁰, Rachael Clark³, ilya Korsunsky²⁹, Christopher Lessard¹ and Kevin Wei³¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Boston, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute, Boston, ⁸Multiple Institutions, Oklahoma City, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹The Ohio State University, Columbus, OH, ¹²University of Pennsylvania, Wynnewood, PA, ¹³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵University of Colorado, Denver, CO, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University of Rochester Medical Center, Canandaigua, NY, ¹⁸New York University School of Medicine, New York, NY, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰UCSF, San Francisco, CA, ²¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²²University of California San Francisco, San Francisco, CA, ²³Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Icahn School of Medicine at Mount Sinai, New York, NY, ²⁶NYU Grossman School of Medicine, New York, ²⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁸Broad Institute of MIT Harvard, Cambridge, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰University of Michigan, Ann Arbor, ³¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Autoimmune diseases affect more than 23.5 million Americans involving nearly every organ system of the human body. To identify shared, unique, and novel pathways…
Abstract Number: 1712 • ACR Convergence 2025
Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman¹, Nicolas Coudray², Xu Han², Morgan Grams², Eric Oermann², Aristotelis Tsirigos² and Jose Scher³, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease that affects both the skin and musculoskeletal system and is frequently associated with a heightened…
Abstract Number: 1443 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
Iain McInnes¹, Koji Kato², Marina Magrey³, Joseph Merola⁴, mitsumasa kishimoto⁵, Derek Haaland⁶, Ivan Lagunes⁷, Laura Coates⁸, Yanxi Liu⁹, Erin Mancl¹⁰, Bhumik Parikh¹¹ and Charles Phillips¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Abbvie. Inc, North Chicago, IL, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶The Waterside Clinic, Oro Medonte, ON, Canada, ⁷Abbvie Inc, North Chicago, IL, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁹Abbvie Inc, Florham Park, NJ, ¹⁰AbbVie, Chicago, IL, ¹¹AbbVie, Hillsborough Township, NJ, ¹²AbbVie Inc, Princeton, NJ
Background/Purpose: We evaluated safety and efficacy of upadacitinib (UPA) versus adalimumab (ADA) at week 260 (5-years) from the long-term extension of SELECT-PsA 1.Methods: Randomized patients…
Abstract Number: 1303 • ACR Convergence 2025
Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Xuemei Tang, Yuting Zhou, Yuxiao Chen, Xinglin Wu and Qiang Luo, Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic)
Background/Purpose: A balanced diet can prevent diseases and promote physical and mental health. Accumulating evidence shows that fruits and vegetables (F&Vs) intake is associated with…

« Previous Page
1
…
7
8
9
10
11
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].